NCT07681713尚未招募3 期
Evaluation of Long-Term Efficacy of Vatiquinone for the Treatment of Friedreich's Ataxia
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 120
- 试验地点
- 9
- 主要终点
- Change From Baseline in Total Modified Friedreich's Ataxia Rating Scale (mFARS) Score at Month 24
研究概览
简要总结
The purpose of this study is to confirm the treatment effects of vatiquinone on the key measures of FA disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 21 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •mFARS ≥20 to ≤70 at Screening (4 weeks prior to Day 1) and Baseline (Day 1).
- •Must be ambulatory as defined by a E7 score of 4 or less on the USS at Screening and Baseline.
- •Documentation that participants reached maximum score on items E4, E5, and E3b on the USS of mFARS at Screening and Baseline.
- •FA diagnosis (homozygous for guanine-adenine-adenine [GAA] repeat expansion in intron-1 of the frataxin gene), confirmed and documented with GAA repeat length for both alleles by clinical genetic testing.
- •Difference in the mFARS score between Screening and Baseline of no more than 4 points.
- •Ability to abstain from strong cytochrome P450 (CYP) 3A4 inducers/inhibitors (for example, ketoconazole, rifampin, St. John's wort, grapefruit juice) for at least 4 weeks prior to Baseline and for the duration of the study.
排除标准
- •Individuals with clinical diagnosis of FA who have point mutations, deletions, or other non-GAA expansion mutations.
- •Allergy to vatiquinone, sesame oil, gelatin (bovine and/or porcine), titanium dioxide, or red iron oxide.
- •Pregnant or lactating participants or those sexually active participants who are unwilling to comply with proper birth control methods; females of childbearing potential must have a negative pregnancy test at Screening and during the Baseline Visit.
- •Comorbidities that may confound study results (for example, fat malabsorption syndrome, other mitochondrial disorder) in the opinion of the investigator.
- •Participation in an interventional clinical study or received investigational drug (other than SKYCLARYS® [omaveloxolone]) within 60 days prior to Screening. Participants may be screened after the exclusionary period of 60 days has passed.
- •Current use of omaveloxolone. Previous use of omaveloxolone will be allowed if:
- •Use was less than 3 cumulative months and participants have been off treatment for >30 days.
- •Use was less than 6 cumulative months and participants have been off treatment for >90 days
- •Previous or concurrent use of other investigational treatment for FA.
- •Participation in any cell or gene therapy-based treatment for FA.
- •Participation in an ongoing study for vatiquinone or current or previous use of vatiquinone.
- •Illicit drug use 30 days prior to Screening and during the study.
- •Note: Other protocol-defined inclusion and exclusion criteria may apply.
研究组 & 干预措施
Vatiquinone
Experimental
Participants will receive vatiquinone capsule at a dose of either 200 milligrams (mg) orally 3 times a day (TID) if weighing ˂25 kilograms (kg) or 400 mg orally TID if weighing ≥25 kg for 24 months.
干预措施: Vatiquinone (Drug)
结局指标
主要结局
Change From Baseline in Total Modified Friedreich's Ataxia Rating Scale (mFARS) Score at Month 24
时间窗: Baseline, Month 24
次要结局
- Change From Baseline in mFARS Subscale Scores (Upright Stability Subscale [USS], Upper Limb [UL], Lower Limb [LL], Bulbar [BUL]) at Month 24(Baseline, Month 24)
- Change From Baseline in Friedreich's Ataxia Rating Scale - Activities of Daily Living (FARS-ADL) Score at Month 24(Baseline, Month 24)
- Change From Baseline in 25-Foot Walk Test (T25FW) at Month 24(Baseline, Month 24)
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)(Baseline up to Month 25)
研究者
研究点 (9)
Loading locations...
相似试验
尚未招募
2/3 期
“A Clinical Study to Assess the Effect of Nirgundi (Vitex negundo) Leaf Extract in the Management of Obesity”CTRI/2026/02/103177Ayurved and Unani Tibbia College and Hospital60
招募中
3 期
A Long-term Study in Children and Teenagers with Ulcerative Colitis or Crohn’s Disease treated with Vedolizumab IV2023-509046-36-00Takeda Development Center Americas Inc.128
招募中
2 期
A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCNCT07269782Shanghai Henlius Biotech60
尚未招募
Phase 3 4
Effect of Vaitrain Basti and Anuvasana Basti With Ashtkatwar Taila in the Management Of SciaticaCTRI/2024/09/074159Dr Sarvapalli Radhakrishnan Rajasthan Ayurved University Kadwar Jodhpur Rajasthan60
招募中
不适用
Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.Bladder CancerNCT07379268Qilu Hospital of Shandong University224